National Genecular Institute

National Genecular Institute (NGI) is a leading biotechnology organization based in Shenzhen, China, specializing in the research, development, and commercialization of fibroblast growth factor (FGF) based therapeutics. Serving as the industrialization arm of the National Engineering Research Center for Genecular Medicine, the institute was founded on the pioneering work of Dr. Xiaokun Li, a prominent figure in growth factor research. NGI has successfully brought several recombinant human growth factors to market in China, including rh-aFGF and rh-bFGF, which are widely utilized for treating burns, chronic wounds, and surgical incisions. The company maintains a robust pipeline extending into metabolic diseases and ophthalmology, leveraging its proprietary protein engineering platform to optimize the stability and efficacy of growth factors. NGI is recognized as a key national-level research center, driving innovation in regenerative medicine and molecular biology.